Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Payers “Need A Bigger Boat” To Take On Pricing Like Sovaldi’s – Kaiser Permanente Exec

This article was originally published in The Pink Sheet Daily

Executive Summary

Kaiser Permanente’s Levine and Memorial Sloan Kettering’s Bach discuss approaches to restraining specialty drug costs at May 29 health care conference. CMS’ Tavenner suggests transparency and collaborating with industry on “appropriate use” can help manage costs of Gilead’s Sovaldi.

You may also be interested in...



India Set To Hear Sovaldi Patent Objections Case

India’s patent office has laid out a list of concerns on a pending Sovaldi application by Gilead Sciences – with the drug maker set to respond.

MSD India's Out-Of-The-Box Hep C Financing: How, Why And What Next?

Merck’s India unit has worked to refine a finance program for Hepatitis C treatments that could rapidly grow patient numbers by solving a financing issue that has bedeviled wider use.

Role Of Cost And Evidence In Value-Based Purchasing Highlighted By Zaltrap Price Adjustment

Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel